Recurrent spinal cord glioblastoma: Salvage therapy with bevacizumab.

Abstract

e12501 Background: Primary spinal cord tumors constitute 2%-4% of all primary CNS malignancies in adults of which less than 5% are glioblastoma. A retrospective evaluation to determine toxicity and response to bevacizumab in patients with recurrent spinal cord glioblastoma. Methods: 6 patients (4 males; 2 females: median age 34 years) with recurrent spinal cord glioblastoma were treated with bevacizumab (10 mg/kg given once every 2 weeks wherein 2 treatments constituted a cycle of therapy). All patients had failed surgery and temozolomide-based chemoradiotherapy and post-radiotherapy temozolomide. Blood counts, chemistry panel, urine protein to creatinine ration and neurologic examination were obtained bi-weekly. Contrast-enhanced spine MRI was performed after 1 cycle of therapy and thereafter following every 2 cycles of bevacizumab. Results: Treatment-related complications included fatigue in 6 patients, constipation in 4, hypertension in 2, thrombophlebitis in 2, and infection without neutropenia in 2. ...